Modification of mesenchymal stem cell derived exosomes and its application prospects in the treatment of eye disease

Authors: Lin Hao,  Wang Ying
DOI: 10.3760/cma.j.cn115989-20200319-00186
Published 2020-10-10
Cite as Chin J Exp Ophthalmol, 2020,38(10): 890-894.

Abstract                              [View PDF] [Read Full Text]

Mesenchymal stem cells (MSCs) were extensively explored as new therapeutic agents in cell-based therapy due to their immunomodulatory and pro-angiogenic characteristics.Exosomes are nanovesicles surrounded by a phospholipid layer.Recent studies have demonstrated that MSCs-derived exosomes (MSCs-exo) and MSCs have similar functions.MSCs-exo are considered as an ideal treatment for multiple ocular diseases including uveitis, glaucoma, retinal and ocular surface diseases.However, with complex contents and diverse functions, exosomes need to be modified with different strategies to avoid rapid clearance by the immune system, reduce side effects, enhance target cell specificity, and improve intracellular delivery efficiency.After the modification of MSCs-exo contents, specific therapeutic factor could be overexpressed in MSCs-exo in order to maximize their therapeutic potential and efficacy for specific eye diseases, which is expected to be a new choice for the treatment of eye diseases.This paper focuses on the applications of MSCs-exo and the current researches of exosomes modification strategies, and discusses the potential application prospects of modified MSCs-exo in the treatment of eye disease.

Key words:

Mesenchymal stem cells derived exosomes; Modification of exosomes; Ophthalmology; Review

Contributor Information

Lin Hao
Aier School of Ophthalmology, Central South University, Changsha 410015, China; Shenyang Aier Eye Hospital, Shenyang 110000, China
Wang Ying
Aier School of Ophthalmology, Central South University, Changsha 410015, China; Shenyang Aier Eye Hospital, Shenyang 110000, China
(Read 174 times, 1 visits today)
Updated: December 26, 2022 — 2:35 am